C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.
1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.
2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.
4 It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).
5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.
2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone.
